Organization
Sydney, NSW, Australia
14 abstracts
Abstract
External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.Org: The University of Texas MD Anderson Cancer Center, The University of Sydney, Melanoma Institute Australia, Royal Prince Alfred Hospital, Sydney, NSW, Australia,
Abstract
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.Org: Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada, University of Western Ontario, London, ON, Canada, Manitoba Prostate Cancer, University of Manitoba, Winnipeg, MB, Canada, CancerCare Manitoba, Winnipeg, MB, Canada, McGill University Health Center, Montreal, QC, Canada, Department of Urology, Dalhousie University, Halifax, NS, Canada, Queen's University, Kingston, ON, Canada, St. Josephs Healthcare, McMaster University, Hamilton, ON, Canada, Northern Alberta Urology Clinic, Edmonton, AB, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Ottawa Hospital, Ottawa, ON, Canada, CIUSSS de l'Estrie – CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, St. Vincent's Hospital Sydney, Sydney, NSW, Australia, Princess Margaret Cancer Centre, University Health Network, Toronto Allergy and Asthma Centre, Oncotelic,
Abstract
Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702—Survival results.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Breast Cancer Trials - Australia and New Zealand, NHMRC Clinical Trials Centre, Monash Health, Bentleigh East, VIC, Australia, Macarthur Cancer Therapy Center,
Abstract
4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.Org: The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia, St. Vincent's Hospital, Darlinghurst, NSW, Australia,
Abstract
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).Org: Melanoma Institute Australia, The University of Sydney, Sydney, Australia, Wollstonecraft, NSW, Australia, Sydney, NSW, Australia,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Org: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia, Sydney, Australia, Garvan Institute of Medical Research,
Abstract
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.Org: University of Linköping, Linköping University Hospital, Sweden, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences,
Abstract
Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.Org: Garvan Institute of Medical Research, Darlinghurst, NSW, Australia, Australian Catholic University, Sydney, NSW, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Charles Gairdner Hospital, Harry Perkins Institute for Medical Research, University of Western Australia & Linear Clinical Research, Melbourne, Australia,
Abstract
A multicentre randomised controlled trial of zoledronic acid for osteoarthritis of the knee with bone marrow lesionsOrg: Menzies Institute for Medical Research, University of Tasmania, Hobart W. Harris, The Queen Elizabeth Hospital Kings Lynn NHS Trust, Woodville,
Abstract
44% OF SWOLLEN JOINTS IN RHEUMATOID ARTHRITIS PATIENTS WITH A MEDIAN OF 10 YEARS OF DISEASE ALSO HAVE JOINT DEFORMITY OR LIMITED MOTION, PRECLUDING RESOLUTION TO A NORMAL JOINTOrg: Rush University Medical Center, Rheumatology, Chicago, IL, United States of America, University of New South Wales,
Abstract
AN AUSTRALIAN PERSPECTIVE OF ARTHRITIS SELF MANAGEMENTOrg: Arthritis Foundation of NSW Australia, Education Department, Sydney, NSW, Australia, Australian National University, Canberra, Australia, Stanford Research Centre,
Abstract
ASSOCIATION OF HEALTHY LIFESTYLES WITH ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY AMONG INDIVIDUALS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY OF THE UK BIOBANKOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, Guangzhou JOYO Pharma, China National Biotec Group,